Unlock instant, AI-driven research and patent intelligence for your innovation.

Variant fc domains and uses thereof

A domain and variant technology, applied in the field of variant Fc domain monomers, can solve problems such as decreased patient compliance and increased cost of health systems

Pending Publication Date: 2022-06-07
CIDARA THERAPEUTICS
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

All of these factors contribute to decreased patient compliance and increased costs to the health system

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Variant fc domains and uses thereof
  • Variant fc domains and uses thereof
  • Variant fc domains and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0448] Example 1. General procedure for the synthesis of azido-Fc

[0449] Prepare PEG4-azido NHS ester solution (0.050M) in DMF / PBS: dissolve 16.75 mg PEG4-azido NHS ester in 0.100 mL of DMF at 0 °C and buffer by adding PBS 1x at 0 °C The solution was diluted to 0.837mL. Other PEG4-azido Fcs with various DAR values ​​were prepared using this solution by adjusting the equivalents of this PEG4-azido NHS ester PBS solution.

[0450] Pretreatment h-IgG1 Fc (107.2 mg in 8.800 mL of pH 7.4 PBS, MW ~ 57891 Da, 1.852 μmol): Fc solution was transferred to four centrifugal concentrators (30,000 MWCO, 15 mL) and diluted with PBS x1 buffer to 15 mL and concentrated to a volume of -1.5 mL. The residue was diluted 1:10 in PBS pH 7.4 and concentrated again. This washing procedure was repeated a total of four times, then diluted to 8.80 mL.

[0451] Preparation of PEG4-azido Fc: 0.050 M PEG4-azido NHS ester in PBS buffer (0.593 mL, 29.6 μmol, 16 equiv) was added to the above h-IgG1 Fc so...

Embodiment 2

[0452] Example 2. Synthesis of Conjugate 1 (including C220S / M252Y / S254T / T256E mutated Fc domains)

[0453] Prepare click reagent solution: 0.0050M CuSO in PBS buffer 4 : 10.0mg CuSO 4 Dissolve in 12.53mL PBS, then take 5.00mL of this CuSO 4 solution and added 43.1 mg BTTAA (CAS# 1334179-85-9) and 247.5 mg sodium ascorbate, resulting in a click reagent solution (0.0050M CuSO4, 0.020M BTTAA and 0.25M sodium ascorbate).

[0454] To the azido-functionalized Fc solution (Example 1; 65.5 mg, 10.0 mL, 1.13 μmol, azido DAR~5.9, SEQ ID NO: 10) in a 15 mL centrifuge tube was added an alkyne-derived small molecule virus inhibitor agent (22.7 mg per Fc azide, 15.2 μmol, 3.0 equiv). After gentle stirring to dissolve all solids, the mixture was treated with click reagent solution (1.80 mL). The resulting mixture was rotated at ambient temperature for 12 hours. The mixture was purified by affinity chromatography on a protein A column followed by size exclusion chromatography. Maldi TOF...

Embodiment 3

[0455] Example 3. Synthesis of Conjugate 2 (including C220S mutated Fc domain)

[0456] This conjugate was prepared by PEG4-azido-Fc (SEQ ID NO: 21, prepared as in Example 1) and a small molecule virus inhibitor in a similar manner to that of Conjugate 1 (Example 2) . Maldi TOF analysis of the purified final product gave an average mass of 62,927 Da (DAR=4.2).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates to variant Fc domain monomers, fusion proteins, conjugates, compositions, and related methods for treating or preventing disease. In particular, the invention is characterized by comprising mutated variant Fc domain monomers located at positions (220) and (252, 254), and / or (256) or (309, 311) and / or (434) numbered according to the Kabat index. The invention also features a variant Fc domain monomer comprising a mutation at a position (220) numbered according to the Kabat index, wherein the variant Fc domain monomer has a length between 200 and 300 amino acid residues and / or a mass between about 20 kDa and about 40 kDa.

Description

Background technique [0001] The utility of many therapeutic agents, such as small molecule therapeutics and biologics, such as peptides, polypeptides, and polynucleotides, is affected by insufficient serum half-life. This requires administration of such therapeutic agents at high frequency and / or higher doses, or the use of sustained-release formulations, to maintain serum levels required for therapeutic effect. Frequent systemic administration of drugs is associated with considerable negative side effects. For example, frequent systemic injections represent considerable discomfort to the subject, pose a high risk of administration-related infections, and may require hospitalization or frequent hospital visits, especially when the therapeutic agent is to be administered intravenously. In addition, in long-term treatment, daily intravenous injection can also lead to considerable side effects of tissue scarring and vascular lesions caused by repeated puncture of blood vessels. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/00A61K39/395C07K16/00
CPCA61K47/68C07K2317/52C07K2317/522C07K2317/524C07K2317/90A61K2039/505A61K2039/545C07K2319/30C07K16/00C07K14/47A61P31/04A61P31/10A61P31/12A61P27/02A61P17/00A61P35/00A61P25/00C07K16/283
Inventor L·W·塔里
Owner CIDARA THERAPEUTICS